VRTX · Earnings call · 2026Q3T · Full report

Povetacicept Launch Readiness

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance null · Surprise 24

Vertex said its IgAN field team was fully hired and trained, with more than 90% having deep nephrology experience and many already conducting disease education. The company described a people-based, technology-enabled patient support program and reported positive payer conversations about unmet need, clinical profile, differentiation, and value. Nephrologists were seeking rapid proteinuria reduction, tolerability, convenient dosing, and seamless access; Vertex believes the low-volume, low-viscosity, at-home monthly autoinjector can differentiate povetacicept. Management also cited a large untreated opportunity, estimating that 75% of IgAN patients have proteinuria above 1 gram.

Key facts

• Povetacicept's IgAN commercial presentation is a 0.46 mL subcutaneous dose every four weeks via at-home autoinjector.
• In a survey of about 25 U.S. adults with IgAN, 96% preferred an autoinjector to a prefilled syringe and 80% preferred dosing every four weeks to weekly.
• Vertex described povetacicept launch readiness as complete, with its field team fully hired and trained; over 90% of the team had deep nephrology experience.
• Vertex built a people-based, technology-enabled support program to help IgAN patients access povetacicept quickly and easily.